PD-L1 and alternative immune checkpoints (AICs) in non-small cell lung cancer (NSCLC): Insights into the tumor immune microenvironment (TIME) and immunotherapy (IO) outcomes. This is an ASCO Meeting ...

Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

A deep-learning serial CT biomarker improves survival prediction in immunotherapy-treated NSCLC and outperforms RECIST. Find ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

Immune checkpoint inhibitors, designed to block tumors from weakening the body’s immune activity, have been found to interfere with immune regulation in the heart. This side effect may lead to an ...

This article is based on a poster originally authored by Smith Frank, Boute Melodie, Ruez Richard, Amandine Gerstenberg and Ramos Corinne. This poster is being hosted on this website in its raw form, ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

Detailed price information for Briacell Therapeutics Corp (BCTX-Q) from The Globe and Mail including charting and trades.